DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger

IntroductionFluoropyrimidines (FP) are the mainstay of colorectal cancer (CRC) treatment, but can cause severe toxicity in up to 40% of patients. Variants in the DPYD gene are associated with these adverse events. A DPYD-guide dose adjustment is now recommended in Europe. This ambispective study aim...

Descripció completa

Dades bibliogràfiques

Autors principals:	Rocío Rosas-Alonso, Nuria Rodríguez Salas, Pablo Perez Wert, Angela Hoyo, Susana Martin-López, Daniel Martínez-Pérez, Iciar Ruiz-Gutiérrez, Diego Jiménez-Bou, Jesús Peña, Pedro Arias, Ana Custodio, Itsaso Losantos-García, Alberto M. Borobia, Jaime Feliu, Ismael Ghanem
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2025-09-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	fluoropyrimidines DPYD colorectal cancer toxicity discontinuation
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1645188/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!